Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study
Open Access
- 1 December 2021
- journal article
- research article
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 9 (24) , 1769
Abstract
Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study Xinrui Chen, Huaqing Wang, Xiuhua Sun, Liping Su, Fengting Liu, Ke Zhao, Liye Xu, Shaohua Wu, Teng SongKeywords
This publication has 31 references indexed in Scilit:
- Comparison of CD20 expression in B‐cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatmentCancer Science, 2012
- Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomasCancer Chemotherapy and Pharmacology, 2012
- HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cellsLeukemia, 2010
- Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selectionBlood, 2010
- Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significanceBlood, 2009
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin’s Lymphoma: Results From the Randomized European CUP TrialJournal of Clinical Oncology, 2003
- The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995